衰老细胞清除药物的临床潜力
衰老细胞清除药物(senolytics)能选择性诱导衰老细胞凋亡,而衰老细胞随增龄在多种组织及慢性病病灶处积累。动物研究显示,遗传或药物清除衰老细胞可延缓、预防或缓解多种增龄相关表型、慢性病、老年综合征及生理韧性丧失。目前衰老细胞清除药物正在概念验证临床试验中接受检验,并正在建立新的临床试验范式,因为以寿命或健康寿命为长期终点不可行。
要点
- 衰老细胞清除药物选择性诱导衰老细胞凋亡,靶向基本衰老机制。
- 动物研究显示清除衰老细胞可缓解衰弱、心功能障碍、糖尿病、骨质疏松等。
- 因长期终点不可行,正开发针对多病共存、衰弱等的新临床试验范式。
核心结论
- 若衰老细胞清除药物或其他靶向基本衰老过程的干预在临床试验中被证明有效且安全,可能通过同时预防或治疗多种疾病和功能缺陷来改变老年医学实践,而非逐一处理。
研究设计与样本
- 本文为综述,未报告系统检索范围;文中提及衰老细胞清除药物正在概念验证临床试验中接受检验,并正在开发新的临床试验范式。
主要发现
- 动物研究中,通过遗传或药物方法靶向衰老细胞可延缓、预防或缓解多种增龄相关表型、慢性病、老年综合征及生理韧性丧失。
- 临床前研究中,清除衰老细胞成功治疗的慢性病症包括衰弱、心功能障碍、血管反应性低下和钙化、糖尿病、肝脂肪变性、骨质疏松、椎间盘退变、肺纤维化和辐射诱导损伤。
关键数值与推荐
- 因以寿命或健康寿命作为长期终点不可行,新临床试验范式包括测试对多病共存、加速衰老样状况、衰老细胞局部积累的疾病、与衰老细胞积累相关的可能致命疾病、增龄相关生理韧性丧失及衰弱的影响。
临床怎么用
- 若临床试验证实有效且安全,衰老细胞清除药物可能实现同时预防或治疗多种疾病和功能缺陷,而非逐一处理。
局限性
- 本文为综述,未报告系统检索范围;所引临床前研究结果尚未在临床试验中证实,衰老细胞清除药物的有效性和安全性仍在概念验证试验中检验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Senolytic drugs are agents that selectively induce apoptosis of senescent cells. These cells accumulate in many tissues with aging and at sites of pathology in multiple chronic diseases. In studies in animals, targeting senescent cells using genetic or pharmacological approaches delays, prevents, or alleviates multiple age-related phenotypes, chronic diseases, geriatric syndromes, and loss of physiological resilience. Among the chronic conditions successfully treated by depleting senescent cells in preclinical studies are frailty, cardiac dysfunction, vascular hyporeactivity and calcification, diabetes mellitus, liver steatosis, osteoporosis, vertebral disk degeneration, pulmonary fibrosis, and radiation-induced damage. Senolytic agents are being tested in proof-of-concept clinical trials. To do so, new clinical trial paradigms for testing senolytics and other agents that target fundamental aging mechanisms are being developed, because use of long-term endpoints such as lifespan or healthspan is not feasible. These strategies include testing effects on multimorbidity, accelerated aging-like conditions, diseases with localized accumulation of senescent cells, potentially fatal diseases associated with senescent cell accumulation, age-related loss of physiological resilience, and frailty. If senolytics or other interventions that target fundamental aging processes prove to be effective and safe in clinical trials, they could transform geriatric medicine by enabling prevention or treatment of multiple diseases and functional deficits in parallel, instead of one at a time.
引用
- Kirkland JL, Tchkonia T, Zhu Y, et al. The Clinical Potential of Senolytic Drugs. J Am Geriatr Soc. 2017. PMID: 28869295. doi:10.1111/jgs.14969
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。